Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Area of Science:

• Oncology
• Translational Medicine
• Clinical Trial Design

Background:

• Growing success of targeted therapy and immunotherapy in advanced lung cancer.
• Renewed interest in applying these treatments to earlier disease stages.
• Neoadjuvant therapy offers potential for greater impact on patient outcomes.

Purpose of the Study:

• Provide a multi-stakeholder perspective on neoadjuvant therapy in lung cancer.
• Highlight opportunities and challenges in neoadjuvant drug development.
• Advocate for standardized approaches to accelerate knowledge acquisition.

Main Methods:

• Review of current neoadjuvant therapy strategies in lung cancer.
• Analysis of challenges and opportunities in neoadjuvant drug development.
• Discussion on the need for harmonized study designs and endpoints.

Main Results:

• Neoadjuvant approach presents unique challenges and opportunities for drug development.
• Standardization of study designs, endpoints, and pathologic response definitions is essential.
• Collaboration among stakeholders is critical for advancing neoadjuvant strategies.

Conclusions:

• Neoadjuvant therapy holds significant potential for improving lung cancer patient outcomes.
• Harmonization of research practices will expedite the development of novel induction strategies.
• Continued dialogue is vital for optimizing neoadjuvant treatment development for high-risk early lung cancer.